BR112012002265A2 - composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios - Google Patents

composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios

Info

Publication number
BR112012002265A2
BR112012002265A2 BR112012002265A BR112012002265A BR112012002265A2 BR 112012002265 A2 BR112012002265 A2 BR 112012002265A2 BR 112012002265 A BR112012002265 A BR 112012002265A BR 112012002265 A BR112012002265 A BR 112012002265A BR 112012002265 A2 BR112012002265 A2 BR 112012002265A2
Authority
BR
Brazil
Prior art keywords
disorders
cancer
diseases
treatment
pharmaceutical compositions
Prior art date
Application number
BR112012002265A
Other languages
English (en)
Other versions
BR112012002265B8 (pt
BR112012002265B1 (pt
Inventor
Dauntel Specht Verwjs
Irene Sophie Tobias
Raymond D Skwierczynski
Vijayalaksmi Ramanan
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42697590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012002265(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of BR112012002265A2 publication Critical patent/BR112012002265A2/pt
Publication of BR112012002265B1 publication Critical patent/BR112012002265B1/pt
Publication of BR112012002265B8 publication Critical patent/BR112012002265B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
BR112012002265A 2009-07-31 2010-07-28 composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios BR112012002265B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23021209P 2009-07-31 2009-07-31
US61/230,212 2009-07-31
PCT/US2010/002109 WO2011014248A1 (en) 2009-07-31 2010-07-28 Pharmaceutical compositions for the treatment of cancer and other diseases or disorders

Publications (3)

Publication Number Publication Date
BR112012002265A2 true BR112012002265A2 (pt) 2016-06-14
BR112012002265B1 BR112012002265B1 (pt) 2021-01-12
BR112012002265B8 BR112012002265B8 (pt) 2021-05-25

Family

ID=42697590

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012002265A BR112012002265B8 (pt) 2009-07-31 2010-07-28 composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios

Country Status (30)

Country Link
US (3) US20110039826A1 (pt)
EP (1) EP2459173B1 (pt)
JP (2) JP2013500965A (pt)
KR (1) KR101762285B1 (pt)
CN (2) CN103893186B (pt)
AR (1) AR077436A1 (pt)
AU (1) AU2010276741B2 (pt)
BR (1) BR112012002265B8 (pt)
CA (1) CA2769531C (pt)
CL (1) CL2012000261A1 (pt)
CO (1) CO6612185A2 (pt)
CR (1) CR20120084A (pt)
EA (1) EA025277B1 (pt)
EC (1) ECSP12011703A (pt)
GE (1) GEP201606513B (pt)
IL (1) IL217839A (pt)
IN (1) IN2012DN01237A (pt)
JO (1) JO3434B1 (pt)
MA (1) MA33533B1 (pt)
MX (2) MX348197B (pt)
MY (1) MY174084A (pt)
NZ (1) NZ598096A (pt)
PE (1) PE20120788A1 (pt)
SG (2) SG177751A1 (pt)
TN (1) TN2012000046A1 (pt)
TW (1) TWI522357B (pt)
UA (1) UA110463C2 (pt)
UY (1) UY32822A (pt)
WO (1) WO2011014248A1 (pt)
ZA (1) ZA201200944B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572784B2 (en) * 2004-05-14 2009-08-11 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression
RU2535032C2 (ru) 2008-12-22 2014-12-10 Милленниум Фармасьютикалз, Инк. Сочетание ингибиторов аврора киназы и анти-cd 20 антител
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
TWI392514B (zh) * 2010-01-29 2013-04-11 Colgate Palmolive Co 具有高微生物效力之不含氟化物及陰離子表面活性劑的潔牙劑
EP2536279A4 (en) 2010-02-19 2013-07-24 Millennium Pharm Inc CRYSTALLINE FORMS OF SODIUM 4 - {[9-CHLORO-7- (2-FLUORO-6-METHOXYPHENYL) -5H-PYRIMIDO [5,4-D] [2] BENZAZEPHIN-2YL] AMINO} -2-METHOXYBENZOATE
AR086656A1 (es) 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
EP2976086B1 (en) 2013-03-22 2020-10-14 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
EP3076963A4 (en) 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
USD797120S1 (en) 2015-08-28 2017-09-12 Samsung Electronics Co., Ltd. Display screen or portion thereof with graphical user interface

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747487A (en) * 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
AU5330698A (en) 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
CA2378646A1 (en) 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies
AR027714A1 (es) * 2000-03-24 2003-04-09 Baker Norton Pharma Uso de sales metalicas para estabilizar composiciones de taxanos.
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US7572784B2 (en) 2004-05-14 2009-08-11 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression
US20070104785A1 (en) * 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
JP5140600B2 (ja) * 2005-12-23 2013-02-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー オーロラキナーゼのアザインドール阻害薬
JP2009542664A (ja) 2006-06-30 2009-12-03 シェーリング コーポレイション Ｐ５３活性を増大させる置換されたピペリジンの使用の方法
BRPI0715423A2 (pt) * 2006-07-21 2013-07-02 Novartis Ag formulaÇÕes para Éteres de benzimidazolil piridila
EP2054413A2 (en) 2006-08-09 2009-05-06 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
US20090203671A1 (en) * 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
RU2535032C2 (ru) * 2008-12-22 2014-12-10 Милленниум Фармасьютикалз, Инк. Сочетание ингибиторов аврора киназы и анти-cd 20 антител
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
EP2536279A4 (en) * 2010-02-19 2013-07-24 Millennium Pharm Inc CRYSTALLINE FORMS OF SODIUM 4 - {[9-CHLORO-7- (2-FLUORO-6-METHOXYPHENYL) -5H-PYRIMIDO [5,4-D] [2] BENZAZEPHIN-2YL] AMINO} -2-METHOXYBENZOATE

Also Published As

Publication number Publication date
JP2015091877A (ja) 2015-05-14
MX2012001196A (es) 2012-03-14
MA33533B1 (fr) 2012-08-01
BR112012002265B8 (pt) 2021-05-25
CA2769531C (en) 2017-11-07
IL217839A0 (en) 2012-03-29
US9127011B2 (en) 2015-09-08
IL217839A (en) 2017-01-31
WO2011014248A1 (en) 2011-02-03
TW201107331A (en) 2011-03-01
ECSP12011703A (es) 2012-03-30
UA110463C2 (ru) 2016-01-12
US20140073630A1 (en) 2014-03-13
SG177751A1 (en) 2012-02-28
CA2769531A1 (en) 2011-02-03
MX348197B (es) 2017-06-05
EP2459173B1 (en) 2018-02-28
AR077436A1 (es) 2011-08-24
AU2010276741B2 (en) 2016-07-14
US20160158244A1 (en) 2016-06-09
KR20120053008A (ko) 2012-05-24
EA025277B1 (ru) 2016-12-30
CR20120084A (es) 2012-06-01
AU2010276741A1 (en) 2012-03-01
SG10201404483VA (en) 2014-10-30
JP6014695B2 (ja) 2016-10-25
TN2012000046A1 (en) 2013-09-19
US20110039826A1 (en) 2011-02-17
CN103893186A (zh) 2014-07-02
ZA201200944B (en) 2015-07-29
CN102548539A (zh) 2012-07-04
EA201270205A1 (ru) 2012-07-30
GEP201606513B (en) 2016-07-25
KR101762285B1 (ko) 2017-07-28
UY32822A (es) 2011-01-31
US9504693B2 (en) 2016-11-29
CO6612185A2 (es) 2013-02-01
TWI522357B (zh) 2016-02-21
PE20120788A1 (es) 2012-07-22
JP2013500965A (ja) 2013-01-10
CL2012000261A1 (es) 2012-08-03
EP2459173A1 (en) 2012-06-06
IN2012DN01237A (pt) 2015-05-15
JO3434B1 (ar) 2019-10-20
MY174084A (en) 2020-03-09
BR112012002265B1 (pt) 2021-01-12
CN103893186B (zh) 2019-07-09
NZ598096A (en) 2014-05-30

Similar Documents

Publication Publication Date Title
BR112012002265A2 (pt) composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
IL245889A0 (en) Sulfonamide derivatives as bcl-2-selective apoptosis inducers for the treatment of cancer and immune diseases
BRPI0917444A2 (pt) composições farmacêuticas de retenção gástrica para o tratamento e prevenção de doenas do snc
SMT201600055B (it) Composizione farmaceutica per il trattamento o la prevenzione del glaucoma
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
BRPI1006116A2 (pt) "agentes indutores da apoptose para o tratamento de câncer e doenças imunes e autoimunes".
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
EP2125855A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES
BRPI1006115A2 (pt) "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes".
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
BR112013015859A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
BRPI0819241A2 (pt) Compostos derivados de amina para o tratamento de distúrbios e doenças oftálmicas
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI1014759A2 (pt) composto útil para o tratamento de doenças degenerativas e inflamatórias
BR112014016389A8 (pt) composições e uso das mesmas para o tratamento de distúrbios e doenças hepáticas
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
IL224215A (en) An integrated drug for the treatment of functional diseases or conditions of the gastrointestinal system
BRPI1008564A2 (pt) métodos e composições para o dignóstico e tratamento de câncer
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
BRPI0917440A2 (pt) composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho
BRPI1009448A2 (pt) combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/07/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF